Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Obicetrapib · FDC, AMG-899

Small molecule · Inhibitor of Cholesteryl ester transfer protein (CETP) · developed by NewAmsterdam Pharma

Phase 3 Most advanced trial
NAMS Developer
8 Registered trials

What is Obicetrapib?

Obicetrapib is a CETP inhibitor that blocks cholesteryl ester transfer protein, a plasma protein that moves cholesteryl esters between lipoproteins. It is studied in combination with ezetimibe and with evolocumab in atherosclerotic cardiovascular disease, hypercholesterolemia and familial hypercholesterolemia.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
FDC, AMG-899, DEZ-001, TA-8995, Repatha
Drug type
Small molecule
Targets
Cholesteryl ester transfer protein (CETP)
Mechanism
Inhibitor of Cholesteryl ester transfer protein (CETP)
Pathways
cholesteryl ester transfer, LDL cholesterol lowering
Therapy area
Cardiovascular, Metabolic
Developer
NewAmsterdam Pharma (NAMS)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
8O74K609HN

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07219602 Phase 3 Lipidemia Active not recruiting NAMS
NCT06305559 Phase 3 Lipidemia Active not recruiting NAMS
NCT06005597 Phase 3 Dyslipidemias Completed NAMS
NCT05202509 Phase 3 Atherosclerotic Cardiovascular Disease Active not recruiting NAMS
NCT06982508 Phase 2 Antioxidant Absorption Recruiting NAMS
NCT06496243 Phase 2 Dyslipidemias Recruiting NAMS
NCT04770389 Phase 2 Dyslipidemias Completed NAMS
NCT06250205 Phase 1 Healthy Volunteers Completed NAMS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Antioxidant AbsorptionAtherosclerotic Cardiovascular DiseaseCoronary Artery DiseaseLipidemiaMetabolic Syndrome (MetS)Plaque, AtheroscleroticType 2 Diabetes (T2DM)ASCVDDyslipidemiasFamilial HypercholesterolemiaHealthy VolunteersHigh CholesterolHypercholesterolemia

Other drugs acting on CETP

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the NAMS page.

Follow NAMS, the company behind Obicetrapib

See NAMS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

NAMS catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.